Blog

Company News

Industry Trends

Laws Regulations

All Categories >

21

2022-12

Hycells Bio | Dedicated to Research on Cell and Animal Models for Drug Development

Shanghai Hycells Biotechnology Co., Ltd. has long been deeply engaged in the cell and gene therapy segment of large-molecule drug development. Since its inception, the company has leveraged a solid customer base and years of accumulated R&D service expertise to establish robust technological barriers, delivering highly satisfactory services that have earned a strong reputation among new-drug R&D enterprises. As a result, it has forged long-term, stable partnerships with numerous leading CROs, cell therapy companies, and gene therapy firms. Moving forward, we will continue to optimize our clinical, technical, and business management systems as well as our service processes, thereby providing collaborative partners in the biopharmaceutical sector with services that meet even higher standards.

2022-12-21

He Yousheng

19

2022-12

To Our Original Aspiration, Embarking on a New Journey | Hycells Biological Relocates to New Headquarters

2022 was an extraordinary year for everyone. Although the pandemic restricted our movements, it only intensified our collective commitment to safeguarding human life and health. In November 2022, Hycells Biotechnology turned a new, milestone chapter in its history by relocating to a brand-new facility—marking a significant leap forward in the company’s manufacturing and R&D capabilities and providing a powerful boost to its sustained growth. Thanks to the concerted efforts of colleagues across all departments, we officially moved into our new premises on November 21, 2022.

2022-12-19

He Yousheng

21

2022-05

Detailed Implementation Rules for the Regulations on the Administration of Human Genetic Resources (Draft for Comments)

2022-05-21

He Yousheng

21

2022-05

Analysis of Shanghai’s April Economic Performance

Due to the impact of the pandemic, Shanghai has implemented district-based static management since 5:00 a.m. on March 28, with the Huangpu River serving as the dividing line, until recently when enterprises began to resume work and production. On May 19, the Shanghai Municipal Bureau of Statistics released economic performance data for April. In April 2022, industrial enterprises above designated size in our city (hereinafter referred to as “industry”) recorded a total industrial output value of RMB 128.617 billion, a year-on-year decrease of 61.5%.

2022-05-21

He Yousheng

08

2022-05

A Trillion-Yuan Blue-Ocean Market: COVID-19 Antigen Self-Testing

To further optimize COVID-19 testing strategies in light of epidemic prevention and control needs, the Comprehensive Group of the State Council Joint Prevention and Control Mechanism has decided to promote a monitoring model of “antigen screening combined with nucleic acid diagnosis,” supplementing nucleic acid testing with antigen testing. On March 11, the Comprehensive Group issued the “Trial Implementation Plan for the Application of COVID-19 Antigen Testing” (hereinafter referred to as the “Plan”), requiring all localities to conscientiously organize and implement it.

2022-05-08

He Yousheng

08

2022-05

This is the best of times for biopharmaceutical CDMOs; this is the worst of times for biopharmaceutical CDMOs.

As another year draws to a close, a review of the domestic biopharmaceutical CDMO sector in 2021 reveals a remarkably dynamic and diverse landscape. Some companies have been acquired, others have secured substantial financing to expand production capacity, some have attracted equity investments from listed firms, while several listed pharmaceutical companies have embarked on strategic transformations to enter the biopharmaceutical CDMO business. A number of firms have already submitted IPO applications that have been accepted for review, others are currently undergoing pre-IPO guidance, and some local industrial parks have established dedicated biopharmaceutical CDMO platforms and awarded contracts to professional operators. Meanwhile, an increasing number of biopharmaceutical companies are venturing into the CDMO space. At present, the industry’s development can only be described as characterized by “intense internal competition” and “unprecedented prosperity.”

2022-05-08

He Yousheng
< 1...21222324 >